Foot and Mouth Disease Virus

dreamstime_13272506 dreamstime_12385533
Foot and Mouth Disease Virus (FMDV) is an acute, highly contagious infection of cloven hooved animals that is present in most parts of the world, often causing extensive epidemics in domestic cattle and swine. The virus can cause persistent infection of the pharynx in cattle, sheep, goats, and other ruminants, and more than 70 species of wild mammals belonging to more than 20 families are susceptible to infection. FMDV is one of the most economically devastating diseases of livestock. The disease is highly contagious and spreads via infected or contaminated animals, products, objects, and people. Animals ingest infected food and are also infected by respiratory aerosols.

Clinical signs in cattle are salivation, anorexia, and lameness caused by painful vesicles in the skin of lips, tongue, gums, notstrils, coronary bands, interdigital spaces, and teats. Vesicles rupture leaving large areas of denuded skin that can become secondarily infected. Decreased milk production also occurs. Because of the large range of animal species affected, the extremely high rate of infectivity, and the fact that virus is shed before clinical signs occur, FMDV is the most feared reportable disease in North American and an outbreak of FMDV would cost billions of dollars in lost production, loss of export markets, loss of meat and dairy products, and loss of animals due to disease eradication measures.

FMDV is an Apthovirus that belongs to the RNA virus family Picornaviridae. The three major capsid proteins of all picornaviruses, VP1, VP2, and VP3, are structurally similar to each other. BMI is applying its Immune Dampening and Refocusing Technology to the FMDV capsid proteins. Biological Mimetics, Inc. (BMI) FMDV veterinary program serves as an animal model for the highly related human rhinovirus application.

Search Site

Virus Developments

BMI is developing an AIDS vaccine and applying its Immune Dampening and Refocusing Technology to the outer HIV envelope glycoprotein gp120/gp41, which is the main mediator of viral fusion and entry with host receptors CD4 and chemokine receptors CCR5 and/or CXCR4.

The Latest Technology

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Research & Development

dreamstime_13272506Biological Mimetics, Inc. research and development includes veterinary applications such as:
Foot and Mouth Disease Virus , Infectious Pancreatic Necrosis Virus,
and
Porcine Reproductive and Respiratory Syndrome Virus.

Company News

blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems
blk triangleMay 2008: BMI is awarded a subcontract for HIV vaccine development through the Henry M Jackson Institute for the Advancement of Military Medicine.
blk triangleJuly 2007: BMI is awarded a subcontract from DARPA through Rice University to study the evolution of pathogens
blk triangleJune 2007: BMI is awarded a subcontract from DARPA through VaxDesign (Orlando, Florida) to study immunogenicity of influenza